// STATE LEGISLATION TRACKER

Arizona SB 1458: pharmacy board; civil penalties

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Failed

State: Arizona
Bill: SB 1458
Session: 57th-2nd-regular
Filed: 2026-01-29
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

SB1458 was changed from a pharmacy-board civil-penalty bill into a PBM patient-steering bill. It appears to have no direct effect on compounded peptides, off-label prescribing, telehealth, NP or naturopath scope, 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to peptide prescribing or compounding rules
Could limit PBM pressure to use affiliated pharmacies
Could protect some prescription-transfer choice and pharmacy data use
Likely little effect on cash-pay compounded peptide access

What to Watch For

✓

Opportunity If revived, anti-steering language could help patients stay with their preferred pharmacy.

Note The bill does not appear to create new peptide-specific restrictions or permissions.

Note Compounded peptide access would still depend mainly on FDA compounding rules and Arizona pharmacy practice rules.

Where the Bill Stands

The bill passed the Senate and got a House HHS do-pass amended/strike-everything vote on March 23, 2026, but later died in committee.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws